Use of AI in Neoantigen Vaccine Development to Drive Market During 2023–2028
According to a new market research study titled “Neoantigens Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Treatment and Therapeutic Specialty,” the market is expected to reach US$ 10,54,783.54 thousand by 2028 from US$ 2,71,428.57 thousand in 2023. It is estimated to grow at a CAGR of 31.2% from 2023 to 2028. The report highlights the trends prevalent in the market and the factors driving the market along with those that act as restraints to its growth. The growth of the market is attributed to some key driving factors such as developments in neoantigen vaccines against cancer and increasing prevalence of cancer. However, the possible side effects associated with neoantigen vaccines are expected to restraint the growth of the market during the forecast years.
Private organizations and companies as well as government associations are equally participating in the development of immunotherapy methods by integrating IT with life sciences. Healthcare IT and neoantigen market players are integrating artificial intelligence (AI) technology with neoantigens to identify patient-specific immunogenic cancer mutations. In May 2020, NEC Corporation, an IT and network technologies company, and Transgene, a company involved in the development of virus-based immunotherapies for cancer treatment, announced to publish their findings in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II) in June 2020. The companies were looking forward to announcing data related to a prediction algorithm that can be used to customize an individualized therapeutic vaccine TG4050 for patients as per their immunogenic cancer mutation is accurate in June 2020 at AACR Virtual Annual Meeting II. The customization of TG4050 would be more specific, and it would be possible for a large set of candidate mutations. The TG4050 was designed by using the myvac technology of Transgene and Neoantigen Prediction System of NEC. The prediction system is an advanced AI technology that has been in use in the field of oncology. The TG4050 is developed to treat solid tumors and is currently in the Phase 1 clinical trial in the US and Europe. Thus, the integration of AI with neoantigen vaccine research is emerging as a key trend in the neoantigen market.
Achilles Therapeutics plc; Advaxis, Inc.; Frame Cancer Therapeutics; Genocea, Gradalis, Inc.; Gritstone Oncology; Immunicum AB; Medigene AG; Ziopharm Oncology, Inc.; and Moderna, Inc. are among the prominent players operating in the neoantigens market.
The report segments the global neoantigens market as follows:
By Treatment
- Combination Therapy
- Mono Therapy
By Therapeutic Specialty
- Gastrointestinal Cancer
- Lung Cancer
- Solid Tumors
- Urinary System Cancers
- Melanoma
- Head and Neck Cancer
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific (APAC)
- Japan
- China
- India
- Australia
- South Korea
- Rest of APAC
- Middle East & Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Rest of MEA
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM
